Abstract
For women with uncomplicated solid organ transplantation, the US Medical Eligibility Criteria for Contraceptive Use consider all methods of contraception category 2 (benefits generally outweigh risks). Pregnancy is not recommended until graft function is stable, and thereafter should be carefully timed in conjunction with a transplant team. For this reason, it is recommended that patients with a history of transplantation use highly effective methods of contraception when not actively trying to conceive. The only types of contraception that have been systematically studied in women after transplantation are combined hormonal contraception and the intrauterine device (IUD). IUDs were historically thought to be contraindicated in a post-transplant population, but modern literature is overwhelmingly reassuring. These studies, though small series, are largely reassuring. Long-acting reversible contraception (LARC) methods are underutilized in this population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
It should be noted that the mechanism of immunosuppression for solid organ transplantation is largely the TNF-alpha pathway, which is different than the protease pathway inhibited by HIV. However, the same concepts apply, namely that immunosuppression does not present a contraindication for most contraceptive use, including IUD. For a full discussion of HIV and contraception, please see Chap. 6.
References
2012 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994–2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
2011 Annual Data Report. http://srtr.transplant.hrsa.gov/annual_reports/2011/. Accessed 22 Dec 2013.
Farber M. Pregnancy and renal transplantation. Clin Obstet Gynecol. 1978;21:931.
Mastrobattista JM, Gomez-Lobo V. Pregnancy after solid organ transplantation. Obstet Gynecol. 2008;112:919.
Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65–85.
Coffin CS, Shaheen AAM, Burak KW, Myers RP. Pregnancy outcomes among liver transplant recipients in the United States: a nationwide case–control analysis. Liver Transpl. 2010;16:56.
Deshpande NA, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, Montgomery RA, et al. Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis. Am J Transplant. 2011;11:2388.
Deshpande NA, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, Cameron AM, et al. Pregnancy outcomes of liver transplant recipients: a systematic review and meta-analysis. Liver Transpl. 2012;18(6):621–9.
Ghazizadeh S, Lessan-Pezeshki M, Khatami M, Mahdavi M, Razeghi E, Seifi S, et al. Unwanted pregnancy among kidney transplant recipients in Iran. Transplant Proc. 2005;37(7):3085–6.
Xu L, Yang Y, Shi JG, Wang H, Qiu F, Peng W, et al. Unwanted pregnancy among Chinese renal transplant recipients. Eur J Contracept Reprod Health Care. 2011;16(4):270–6.
Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception. 2011;84(5):e11–6.
Gill JS, Zalunardo N, Rose C, Tonelli M. The pregnancy rate and live birth rate in kidney transplant recipients. Am J Transplant. 2009;9:1541.
Curtis KM, Jamieson DJ, Peterson HB, Marchbanks PA. Adaptation of the World Health Organization’s medical eligibility criteria for contraceptive use for use in the United States. Contraception. 2010;82(1):3.
McKay DB, Josephson MA, Armenti VT, August P, Coscia LA, Davis CL, et al. Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant. 2005;5(7):1592–9.
Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG. 2001;108:784.
Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144e1.
Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-RodrÃguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345:561.
U.S. Selected Practice Recommendations for Contraceptive Use, 2013. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm. Accessed 22 Dec 2013.
Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev. 2001;(2):CD001327. doi:10.1002/14651858.CD001327.
Leticee N, Viard J-P, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012;85(4):425–7.
Kaunitz AM, Grimes DA. Removing the black box warning for depot medroxyprogesterone acetate. Contraception. 2011;84:212.
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18n:1319–28.
Pietrzak B, Kaminski P, Wielgos M, Bobrowska K, Durlik M. Combined oral contraception in women after renal transplantation. Neuro Endocrinol Lett. 2006;27:679.
Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z, Kaminski P, Wielgos M, Pazik J. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplant Proc. 2007;39:2759.
Jabiry-Zieniewicz Z, Bobrowska K, Kaminski P, Wielgos M, Zieniewicz K, Krawczyk M. Low-dose hormonal contraception after liver transplantation. Transplant Proc. 2007;39:1530.
Paternoster DM, Riboni F, Bertolino M, Garofalo G, Lazzarich E, Surico N, et al. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplant Proc. 2010;42:1162.
Azasan Prescribing Information (PI)—azasan-pi.pdf. http://cdn.salix.com/shared/pi/azasan-pi.pdf. Accessed 22 Dec 2013.
CellCept. http://www.cellcept.com/cellcept/index-h.htm. Accessed 22 Dec 2013.
Trussell J. Contraceptive Efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M, editors. Contraceptive technology. Revised 20th ed. New York, NY: Ardent Media; 2011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Krajewski, C.M., Burke, A.E. (2014). Contraception for Women with a History of Solid Organ Transplantation. In: Allen, R., Cwiak, C. (eds) Contraception for the Medically Challenging Patient. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1233-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1233-9_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1232-2
Online ISBN: 978-1-4939-1233-9
eBook Packages: MedicineMedicine (R0)